SEC Filings

Form 8-K
EDGE THERAPEUTICS, INC. filed this Form 8-K on 11/26/2018
Document Outline
Entire Document (3471.2 KB)
Subdocument 1 - 8-K - 8-K
Page 1 - UNITED STATES
Page 2 - N/A
Page 3 - Forward-Looking Statements
Page 4 - Important Additional Information Will be Filed with the SEC
Page 5 - *The schedules and exhibits to the merger agreement have been omitted pursuant to Item 601(b)(2) of
Subdocument 2 - EX-2.1 - EXHIBIT 2.1
Page 1 - Exhibit 2.1
Page 2 - TABLE OF CONTENTS
Page 3 - TABLE OF CONTENTS
Page 4 - TABLE OF CONTENTS
Page 5 - TABLE OF CONTENTS
Page 6 - TABLE OF CONTENTS
Page 7 - THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATIONAgreementEdge Therapeutics, Inc.ParentECHOS MERG
Page 8 - Exhibit B-2Parent Stockholder Support Agreement
Page 9 - Certificate of Incorporation and Bylaws; Directors and Officers.
Page 10 - Merger Consideration
Page 11 - provided, however
Page 12 - N/A
Page 13 - Appraisal Rights
Page 14 - Pro-Forma Capitalization.
Page 15 - Organizational Documents.
Page 16 - Capitalization
Page 17 - Financial Statements
Page 18 - Company Financials
Page 19 - Absence of Undisclosed Liabilities.Liability
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - Agreements, Contracts and Commitments
Page 24 - Compliance; Permits; Restrictions
Page 25 - Company Permits
Page 26 - HIPAA
Page 27 - Legal Proceedings; Orders
Page 28 - N/A
Page 29 - Employee and Labor Matters; Benefit Plans
Page 30 - N/A
Page 31 - N/A
Page 32 - Environmental Matters.
Page 33 - No Brokers Fees.
Page 34 - Information Technology; Data Privacy
Page 35 - Section 3.REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB
Page 36 - Authority; Binding Nature of Agreement.
Page 37 - Capitalization
Page 38 - N/A
Page 39 - SEC Filings; Financial Statements
Page 40 - Absence of Undisclosed Liabilities.
Page 41 - Intellectual Property
Page 42 - N/A
Page 43 - Agreements, Contracts and Commitments.
Page 44 - Parent Material Contract
Page 45 - N/A
Page 46 - Legal Proceedings; Orders
Page 47 - N/A
Page 48 - Employee and Labor Matters; Benefit Plans
Page 49 - N/A
Page 50 - N/A
Page 51 - Environmental Matters.
Page 52 - Transactions with Affiliates.
Page 53 - Contract Termination Fees; Severance.Parent Contract Termination PaymentsParent Severance Payments
Page 54 - Section 4.CERTAIN COVENANTS OF THE PARTIES
Page 55 - N/A
Page 56 - Operation of the Company s Business
Page 57 - N/A
Page 58 - Access and Investigation
Page 59 - Parent Non-Solicitation
Page 60 - Company Non-Solicitation
Page 61 - Section 5.ADDITIONAL AGREEMENTS OF THE PARTIES
Page 62 - DLADechertTax Representation Letter
Page 63 - Company Information Statement; Stockholder Written Consent
Page 64 - Parent Stockholders Meeting
Page 65 - Parent Change in Circumstance Notice
Page 66 - Regulatory Approvals.
Page 67 - Parent Options and Parent RSUs
Page 68 - Indemnification of Officers and Directors
Page 69 - Additional Agreements
Page 70 - Disclosure
Page 71 - Tax Matters
Page 72 - Directors and OfficersExhibit CExhibit CExhibit CParent DesigneesExhibit C
Page 73 - Allocation Certificate
Page 74 - Stockholder Litigation
Page 75 - Parent Net Cash Response DateCompany Dispute Notice
Page 76 - Accounting Firm
Page 77 - Reverse SplitReverse Split
Page 78 - Section 7.ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB
Page 79 - FIRPTA Certificate
Page 80 - Performance of Covenants
Page 81 - Lock-Up AgreementsExhibit D-2Parent Lock-Up Agreement
Page 82 - providedprovidedfurther
Page 83 - Effect of Termination
Page 84 - The Wall Street Journal
Page 85 - Waiver
Page 86 - Attorneys Fees
Page 87 - Cooperation
Page 88 - No Third Party Beneficiaries
Page 89 - Remainder of page intentionally left blank
Page 90 - IN WITNESS WHEREOF,
Page 91 - IN WITNESS WHEREOF,
Page 92 - EXHIBIT A
Page 93 - Agreement
Page 94 - CompanyERISA Affiliate
Page 95 - Company Net Cash
Page 96 - Company Unaudited Interim Balance Sheet
Page 97 - Enforceability Exceptions
Page 98 - N/A
Page 99 - GAAP
Page 100 - Intellectual PropertyPatentsCopyrightsTrademarksProprietary Information
Page 101 - Merger Sub Board
Page 102 - Parent Contract
Page 103 - Parent Net Cash
Page 104 - Parent Transaction Expenses
Page 105 - Permitted Encumbrance
Page 106 - Superior Offer
Page 107 - Treasury Regulations
Page 108 - N/A
Page 109 - N/A
Subdocument 3 - EX-2.2 - EXHIBIT 2.2
Page 1 - Exhibit 2.2
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - [Remainder of page intentionally left blank]
Page 6 - Signature Page to Support Agreement
Page 7 - Signature Page to Support Agreement
Page 8 - Schedule 1
Page 9 - Exhibit A
Subdocument 4 - EX-2.3 - EXHIBIT 2.3
Page 1 - Exhibit 2.3
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - [Remainder of page intentionally left blank]
Page 6 - Signature Page to Support Agreement
Page 7 - Signature Page to Support Agreement
Page 8 - Schedule 1
Subdocument 5 - EX-99.1 - EXHIBIT 99.1
Page 1 - Exhibit 99.1
Page 2 - Versamune Platform
Page 3 - Board of Directors
Page 4 - About Edge Therapeutics, Inc.
Page 5 - Additional Information about the Merger and Where to Find It
Subdocument 6 - EX-99.2 - EXHIBIT 99.2
Page 1 - Exhibit 99.2
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - Versamune Unique Multiple Mechanisms of Action Promote In-vivo Killer T-cell Induction Priming and t
Page 8 - N/A
Page 9 - N/A
Page 10 - Versamune Competitive Barriers Patent Protection in U.S., EU, Asia Patent Protection in U.S., EU, As
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts